6h agoThe FlyBEARISH 34General
Archived explainer. For the current picture see today's RCUS page.
Why Is ARCUS BIOSCIENCES IN (RCUS) Stock Down Today?
By the Top Tier Newswire AI Desk · October 21, 2026 at 1:57 PM ET · reviewed against 14 wire stories
ARCUS BIOSCIENCES IN (RCUS) is down -15.28% in the latest session. Our newswire has captured 14 stories on RCUS across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Arcus Biosciences shares fell 15.28% to $20.12 on Tuesday. The decline followed the release of new data for its kidney cancer drug casdatifan, which showed promising results but left the stock trading well below recent analyst price targets.
What Happened
The company presented updated data from the ARC-20 platform study for casdatifan in kidney cancer. The results indicated that casdatifan combinations demonstrated superior or competitive progression-free survival and response rates compared to historical benchmarks. Additionally, the data revealed a nearly three-year median overall survival in heavily pretreated patients. Despite these positive clinical signals, the stock experienced a sharp reversal after opening higher. Analysts responded with mixed but generally positive actions. Truist raised its price target to $41 from $40 while maintaining a Buy rating. Citi increased its target to $50 from $45. Wedbush raised its target to $49 from $43 and kept its Outperform rating.
What The Data Shows
The session began with a 1.3% gap up to $24.05, reaching a high of $24.47 at 9:30 AM ET. The stock then slid to a session low of $20.06 at 1:55 PM ET. Volume reached 1.6 million shares, which is 1.1 times the three-month daily average. Fundamentals show the company has a market cap of $2.8 billion and remains unprofitable with a trailing twelve-month EPS of negative $3.86. Revenue declined 55.3% over the same period, and the net margin stands at negative 393.2%. The stock printed 65 fresh 52-week lows on October 21, 2026, within a 52-week range of $16.35 to $31.73. Insider activity includes one sale by Chief Accounting Officer Alexander Azoy on August 21, 2026. Congressional records show one sale by Donald J. Trump on July 29, 2026.
What To Watch
Investors will monitor upcoming Phase 3 trials for casdatifan, which remain pending. The market will also watch for further analyst reactions to the clinical data and how the stock stabilizes relative to the recent 52-week lows.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RCUS by the numbers
Last: $20.12Session: -15.28%7 sessions: -21.53%Coverage: 14 stories / 8 sourcesAI sentiment: 59/100 (bullish)Mkt cap: $2.8B52w: $16.35 to $31.73
The headlines behind the move
8h agoInvesting.com Analyst RatingsBULLISH 64Analyst
Truist raises Arcus Biosciences stock price target on drug data
Truist raises Arcus Biosciences stock price target on drug data
10h agoSeeking AlphaBULLISH 63Analyst
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Arcus Biosciences casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks. Learn why RCUS stock is a buy.
11h agoThe FlyBULLISH 63Analyst
Arcus Biosciences price target raised to $41 from $40 at Truist
12h agoThe FlyBULLISH 64Analyst
Arcus Biosciences price target raised to $50 from $45 at Citi
1d agoSeeking AlphaBULLISH 58Product/PR
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy October 20, 2026 8:30 AM EDTCompany...
1d agoSeeking AlphaBULLISH 64Analyst
Arcus rises as analysts cheer ARC-20 platform data for kidney cancer drug
Arcus Biosciences (RCUS) stock rises as the company updates ARC-20 platform study data for kidney cancer drug casdatifan. Read more here.
1d agoInvestors.comBULLISH 74Product/PR
Arcus Biosciences Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on RCUS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RCUS move explainers: 2026-10-21 · 2026-10-20 · 2026-09-11 · 2026-09-10